Country: United States
Language: English
Source: NLM (National Library of Medicine)
LISINOPRIL (UNII: E7199S1YWR) (LISINOPRIL ANHYDROUS - UNII:7Q3P4BS2FD)
BluePoint Laboratories
LISINOPRIL
LISINOPRIL 2.5 mg
ORAL
PRESCRIPTION DRUG
Lisinopril tablets are indicated for the treatment of hypertension in adult patients and pediatric patients 6 years of age and older to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety
Lisinopril Tablets, USP, for oral administration, are available as 2.5 mg White, round, biconvex, uncoated tablets debossed “E 25” on one side and plain on the other side and supplied as: NDC 68001-272-00 bottles of 100 NDC 68001-272-08 bottles of 1000 5 mg Pink, capsule shaped, uncoated tablets, scored and debossed “E54 ” on one side and scored on the other side and supplied as: NDC 68001-267-00 bottles of 100 NDC 68001-267-08 bottles of 1000 10 mg Pink, round, biconvex, uncoated tablets debossed “E 101” on one side and plain on the other side and supplied as: NDC 68001-268-00 bottles of 100 NDC 68001-268-08 bottles of 1000 20 mg Peach, round, biconvex, uncoated tablets debossed “E 102” on one side and plain on the other side and supplied as: NDC 68001-269-00 bottles of 100 NDC 68001-269-08 bottles of 1000 30 mg Red, round, biconvex, uncoated tablets debossed “E 103” on one side and plain on the other side and supplied as: NDC 68001-270-00 bottles of 100 40 mg Yellow, round, biconvex, uncoated tablets debossed “E 104” on one side and plain on the other side and supplied as: NDC 68001-271-00 bottles of 100 NDC 68001-271-08 bottles of 1000 Storage Store at 20º to 25ºC (68º to 77ºF) [see USP Controlled Room Temperature]. Protect from moisture, freezing and excessive heat. Dispense in a tight container.
Abbreviated New Drug Application
LISINOPRIL- LISINOPRIL TABLET BLUEPOINT LABORATORIES ---------- HIGHLIGHTS OF PRESCRIBING INFORMATION THESE HIGHLIGHTS DO NOT INCLUDE ALL THE INFORMATION NEEDED TO USE LISINOPRIL TABLETS SAFELY AND EFFECTIVELY. SEE FULL PRESCRIBING INFORMATION FOR LISINOPRIL TABLETS. LISINOPRIL TABLETS, FOR ORAL USE INITIAL U.S. APPROVAL: 1988 WARNING: FETAL TOXICITY _SEE FULL PRESCRIBING INFORMATION FOR COMPLETE BOXED WARNING._ • • INDICATIONS AND USAGE Lisinopril tablets are an angiotensin converting enzyme (ACE) inhibitor indicated for: • • • DOSAGE AND ADMINISTRATION • • • • • DOSAGE FORMS AND STRENGTHS Tablets: 2.5 mg, 5mg, 10 mg, 20 mg, 30 mg, 40 mg (3) CONTRAINDICATIONS • • • WARNINGS AND PRECAUTIONS • • • • • ADVERSE REACTIONS Common adverse reactions (events 2% greater than placebo) by use. • • When pregnancy is detected, discontinue lisinopril as soon as possible. (5.1) Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus. (5.1) Treatment of hypertension in adults and pediatric patients 6 years of age and older (1.1) Adjunct therapy for heart failure (1.2) Treatment of Acute Myocardial Infarction (1.3) Hypertension: Initial adult dose is 10 mg once daily. Titrate up to 40 mg daily based on blood pressure response. Initiate patients on diuretics at 5 mg once daily (2.1) Pediatric patients with glomerular filtration rate greater than 30 mL/min/1.73m : Initial dose in patients 6 years of age and older is 0.07 mg per kg (up to 5 mg total) once daily (2.1) 2 Heart Failure: Initiate with 5 mg once daily. Increase dose as tolerated to 40 mg daily (2.2) Acute Myocardial Infarction (MI): Give 5 mg within 24 hours of MI. Followed by 5 mg after 24 hours, then 10 mg once daily (2.3) Renal Impairment: For patients with creatinine clearance greater than or equal to 10 mL/min and less than or equal to 30 mL/min, halve usual initial dose. For patients with creatinine clearance less than 10 mL/min or on hemodialysis, the recommended initial dos Read the complete document